MD, Shanghai Jiaotong University Medical School, China
Basic and translational cancer research with a focus on understanding molecular mechanisms underlying cancer therapy resistance.
Lei Duan, MD, is an assistant professor in the Department of Anatomy & Cell Biology at Rush University Medical Center. Duan received his MD degree from Shanghai Jiaotong University Medical School, China. He received his postdoctoral training at Harvard Medical School in signal transduction and cancer biology. Duan has conducted translational cancer research at Rush over the past eight years with a focus on understanding endocrine therapy resistance in estrogen receptor-positive breast cancer.
Complete list of published work on PubMed
Complete list of published work on Scopus
1. Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent
metabolism through the pentose phosphate pathway that inhibits apoptosis in
response to Nutlin-3a. J Mol Cell Biol. 2017 Nov 27. doi: 10.1093/jmcb/mjx051.
[Epub ahead of print] PubMed [citation] PMID: 29190376
2. Duan L, Maki CG. The IGF-1R/AKT pathway determines cell fate in response to p53.
Transl Cancer Res. 2016 Dec;5(6):664-675. doi: 10.21037/tcr.2016.09.16. PubMed
[citation] PMID: 28966916, PMCID: PMC5617345
3. Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT
pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther.
2017 Nov 2;18(11):895-903. doi: 10.1080/15384047.2017.1345397. Epub 2017 Jul 11.
PubMed [citation] PMID: 28696156, PMCID: PMC5710671
4. Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the
IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines
cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway
inhibitor. Oncotarget. 2016 May 10;7(19):27511-26. doi: 10.18632/oncotarget.8484.
PubMed [citation] PMID: 27050276, PMCID: PMC5053668
5. Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Modeling the Etiology
of p53-mutated Cancer Cells. J Biol Chem. 2016 May 6;291(19):10131-47. doi:
10.1074/jbc.M116.724781. Epub 2016 Mar 28. PubMed [citation] PMID: 27022024,
PMCID: PMC4858965
6. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A,
Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R,
Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM,
Ait-Si-Ali S, Akematsu T, et al. Guidelines for the use and interpretation of
assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi:
10.1080/15548627.2015.1100356. No abstract available. Erratum in: Autophagy.
2016;12(2):443. Selliez, Iban [corrected to Seiliez, Iban]. PubMed [citation]
PMID: 26799652, PMCID: PMC4835977
7. Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. p53-regulated
autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015
Sep 15;6(27):23135-56. PubMed [citation] PMID: 26337205, PMCID: PMC4695109
8. Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Increasing cisplatin sensitivity
by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther.
2014;15(12):1600-12. doi: 10.4161/15384047.2014.961876. PubMed [citation] PMID:
25482935, PMCID: PMC4623033
9. Duan L, Danzer B, Levenson VV, Maki CG. Critical roles for nitric oxide and ERK
in the completion of prosurvival autophagy in 4OHTAM-treated estrogen
receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28;353(2):290-300.
doi: 10.1016/j.canlet.2014.07.031. Epub 2014 Jul 25. PubMed [citation] PMID:
25069039, PMCID: PMC4827626
10. Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The
prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for
rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug
1;289(31):21694-705. doi: 10.1074/jbc.M114.550038. Epub 2014 Jun 16. PubMed
[citation] PMID: 24936056, PMCID: PMC4118128
11. Ortega-Cava CF, Raja SM, Laiq Z, Bailey TA, Luan H, Mohapatra B, Williams SH,
Ericsson AC, Goswami R, Dimri M, Duan L, Band V, Naramura M, Band H. Continuous
requirement of ErbB2 kinase activity for loss of cell polarity and lumen
formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast
cancer. J Carcinog. 2011;10:29. doi: 10.4103/1477-3163.90443. Epub 2011 Nov 30.
PubMed [citation] PMID: 22190871, PMCID: PMC3243085
12. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi
AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in
combination with ErbB2-targeted therapeutics for treatment of
ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011 Jan 15;11(2):263-76.
Epub 2011 Jan 15. PubMed [citation] PMID: 21088503, PMCID: PMC3047084
13. Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV.
Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to
4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast
cancer cells. J Biol Chem. 2011 Jan 28;286(4):2864-76. doi:
10.1074/jbc.M110.143271. Epub 2010 Nov 17. PubMed [citation] PMID: 21087932,
PMCID: PMC3024782
14. Duan L, Raja SM, Chen G, Virmani S, Williams SH, Clubb RJ, Mukhopadhyay C, Rainey MA, Ying G, Dimri M, Chen J, Reddi AL, Naramura M, Band V, Band H. Negative
regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF
receptor-mediated epithelial cell adherens junction dynamics and cell migration.
J Biol Chem. 2011 Jan 7;286(1):620-33. doi: 10.1074/jbc.M110.188086. Epub 2010
Oct 12. PubMed [citation] PMID: 20940296, PMCID: PMC3013022
15. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, Rainey MA, Dimri M,
Ortega-Cava CF, Zhao X, Clubb RJ, Tu C, Reddi AL, Naramura M, Band V, Band H.
Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating
mammary epithelial acinar architecture. J Biol Chem. 2010 Jan 8;285(2):1555-68.
doi: 10.1074/jbc.M109.057976. Epub 2009 Oct 13. PubMed [citation] PMID: 19826000,
PMCID: PMC2801280
16. Zhao X, Lu L, Pokhriyal N, Ma H, Duan L, Lin S, Jafari N, Band H, Band V.
Overexpression of RhoA induces preneoplastic transformation of primary mammary
epithelial cells. Cancer Res. 2009 Jan 15;69(2):483-91. doi:
10.1158/0008-5472.CAN-08-2907. PubMed [citation] PMID: 19147561, PMCID:
PMC2792911
17. Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M,
Band V, Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on
platelet-derived growth factor receptor beta provides a dual mechanism of
negative regulation. J Biol Chem. 2007 Oct 5;282(40):29336-47. Epub 2007 Jul 9.
PubMed [citation] PMID: 17620338
18. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, Goswami R, Fernandes N, Gao Q, Dimri GP, Band V, Band H. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant
three-dimensional acinar structure and invasive behavior. Cancer Res. 2007 May
1;67(9):4164-72. PubMed [citation] PMID: 17483327
19. Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1
activation and angiogenesis. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5413-8. Epub 2007 Mar 19. PubMed [citation] PMID: 17372230, PMCID:
PMC1828708
20. Gan H, He X, Duan L, Mirabile-Levens E, Kornfeld H, Remold HG. Enhancement of
antimycobacterial activity of macrophages by stabilization of inner mitochondrial
membrane potential. J Infect Dis. 2005 Apr 15;191(8):1292-300. Epub 2005 Mar 14.
PubMed [citation] PMID: 15776376
21. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The Cbl family and other ubiquitin
ligases: destructive forces in control of antigen receptor signaling. Immunity.
2004 Jul;21(1):7-17. Review. PubMed [citation] PMID: 15345216
22. Ghosh AK, Reddi AL, Rao NL, Duan L, Band V, Band H. Biochemical basis for the
requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation
of a target tyrosine kinase. J Biol Chem. 2004 Aug 20;279(34):36132-41. Epub 2004
Jun 18. PubMed [citation] PMID: 15208330
23. Miura-Shimura Y, Duan L, Rao NL, Reddi AL, Shimura H, Rottapel R, Druker BJ,
Tsygankov A, Band V, Band H. Cbl-mediated ubiquitinylation and negative
regulation of Vav. J Biol Chem. 2003 Oct 3;278(40):38495-504. Epub 2003 Jul 24.
PubMed [citation] PMID: 12881521
24. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N,
Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M,
Gu H, Band V, Band H. Cbl-mediated ubiquitinylation is required for lysosomal
sorting of epidermal growth factor receptor but is dispensable for endocytosis. J
Biol Chem. 2003 Aug 1;278(31):28950-60. Epub 2003 May 18. PubMed [citation] PMID:
12754251
25. Duan L, Gan H, Golan DE, Remold HG. Critical role of mitochondrial damage in
determining outcome of macrophage infection with Mycobacterium tuberculosis. J
Immunol. 2002 Nov 1;169(9):5181-7. PubMed [citation] PMID: 12391235
26. Duan L, Gan H, Arm J, Remold HG. Cytosolic phospholipase A2 participates with
TNF-alpha in the induction of apoptosis of human macrophages infected with
Mycobacterium tuberculosis H37Ra. J Immunol. 2001 Jun 15;166(12):7469-76. PubMed
[citation] PMID: 11390500
1R01CA200232-01A1, NCI
Maki, Carl (PI)
05/01/15-04/30/21
TARGETING PROLYL PEPTIDASES IN TAMOXIFEN RESISTANT BREAST CANCER
This project is to study the mechanism underlying prolylpepdidase-regulated activation of PI3K-AKT-mTOR pathway, the effect of a prolylpeptidase inhibitor on treatment of endocrine resistant breast tumors, and the prognostic value of prolylpeptidase expression in breast cancer patients.
Role: Co-Investigator
NIH R21CA273658
Maki, Carl (PI)
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer.
Role: Co-Investigator